In this first-in-child phase 1 study of lorlatinib given alone or in combination with chemotherapy, lorlatinib was found to be safe and tolerable in pediatric, adolescent and adult patients with relapsed or refractory ALK-mutated or ALK-amplified neuroblastoma. The gene discussed is ALK; the disease is neuroblastoma.